📣 Try out the NEW Gateway to Research and let us know what you think.

We're looking for users to test the new service during August and September and share their feedback. Express your interest by completing this short form.

Favipiravir, lopinavir-ritonavir or combination therapy (FLARE): a randomised, double blind, 2x2 factorial placebo-controlled trial of early antiviral therapy in COVID-19 (2022)

First Author: Lowe D

Attributed to: MICA: Pharmacokinetic/Pharmacodynamic (PKPD) Model Development to Inform SARS-CoV-2 Antiviral Development funded by COVID

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1101/2022.02.11.22270775

Publication URI: http://dx.doi.org/10.1101/2022.02.11.22270775

Type: Preprint